COST OF
ONCOLYTIC VIRUS TREATMENT
T-VEC's list price across a six-month course looks financially catastrophic. The actual out-of-pocket cost for most insu
analyticsAt a Glance
- check_circleT-VEC (Imlygic) costs approximately $65,000 per treatment course in the United States
- check_circleH101 (Oncorine) is approved and available in China at significantly lower cost
- check_circleTrial participation in oncolytic virus studies often covers drug costs
- check_circleCancerFax can help identify cost-accessible oncolytic virus programmes globally
The List Price Is Not What Most Patients Pay
Patients who encounter T-VEC's list price without the coverage and assistance context reach a conclusion β this treatment is unaffordable β before the actual cost conversation has happened. That conclusion is often wrong.
βStarting financial support engagement before treatment begins β not after the first bill β is what makes the difference.β
Coverage and Assistance Options
Multiple mechanisms exist to reduce or eliminate T-VEC out-of-pocket costs. Each requires proactive engagement.
Commercial Insurance Prior Authorization
Required by most payers. Initial denials occur regularly and are frequently overturned on first appeal with an oncologist's clinical letter. Start the authorisation process when treatment is first discussed β before the first scheduled injection.
Medicare Part B
T-VEC is covered as a physician-administered biologic under Medicare Part B. Standard 20% cost-sharing after the annual deductible.
Amgen Assist 360
Manufacturer patient assistance programme. Provides T-VEC at no cost or reduced cost to patients meeting income and insurance eligibility criteria. Processing takes approximately one to two weeks. Must be initiated before treatment starts.
Clinical Trial Enrollment
Investigational treatment in industry-sponsored trials is provided at no cost to participants. For non-melanoma cancers, clinical trial enrollment is both the access pathway and the cost solution simultaneously.
Melanoma Nonprofit Assistance
Melanoma Research Foundation, Patient Advocate Foundation, HealthWell Foundation: financial assistance for treatment-related costs beyond the drug β transportation, lodging, co-payment assistance.
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About the Cost of Oncolytic Virus Therapy?
CancerFax helps patients navigate insurance authorisation, manufacturer assistance programmes, and cost planning for T-VEC and oncolytic virus clinical trials.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.